ALSO NOTED: Dana-Farber to raise $1B; NeuroSolutions inks new pact;and much more...

> The Dana-Farber Cancer Institute has begun a campaign to raise $1 billion. Release

> NeuroSolutions has inked a two-year pact with an unnamed U.K. biopharmaceutical company. Report

> The FDA has issued an approvable letter for a reformulated version of Avanir's antipsychotic drug FazaClo. Release

> China's Sinovac Biotech has clarified the restructuring of a subsidiary. Release

> Isonics is selling its life sciences division. Report

And Finally... A new study of DTC ads for drugs concludes that they often ignore critical information. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.